Kornimate/medical-research-clean huggingface dataset:
ngal and hepcidin levels in hemodialysis patients in assiut university hospital

Conditions: CKD (Chronic Kidney Disease) Stage 5D

Summary: to assess the pattern of ngal and hepicidin in relation to anemia in end stage renal disease patients on regular hemodialysis in assiut university hospital and study the relation between both ngal and hepicidin.

patients with chronic kidney disease have a chronic inflammatory state, due to many factors e.g. enhancedincidence of infections, the uremic milieu, elevated levels of proinflammatory cytokines, frequent presence of widespread arteriosclerosis, etc. iron metabolism is disturbedin chronic inflammatory diseases.alteredngal levels in hemodialysis patients was probablydue to the fact that this protein was involved in ironmetabolism and suggested that ngal might be anew tool in the assessment of iron deficiency.another study found in multipleregression analysis that; residual renal function, hepcidin,creatinine and hscrp were predictors of serum ngal inhemodialyzed patients. they concluded that ngal is highly induced in dialyzed patients and could reflect both kidney function and iron metabolism.several studies suggested that hepcidin plays a role as anegative regulator of intestinal iron absorption and ironrelease from macrophages. hepcidin controls intestinal ironabsorption by regulating ferroportin expression on thebasolateral membrane of enterocytes .hepicidin is also an acute phase reactant.both ngal and hepcidin are elevated inchronic kidney disease,not only through ironmetabolism, but both are also associated with inflammationand may be related to anemia. possible relationship between ngal and hepicidin is still under study.

Eligibility criteria:
inclusion criteria: for group 1: 1. adults \> 18 years. 2. age and sex matched. 3. no active infection or inflammation. for group 2: 1. adults \> 18 years. 2. esrd patients on regular hemodialysis. 3. hgb \< 11g/dl. 4. no apparent infection or inflammation. for group 3: 1. adults \> 18 years. 2. esrd patients on regular hemodialysis. 3. hgb ≥ 11g/dl. 4. no apparent infection or inflammation. exclusion criteria: 1. children and those \>60 years. 2. pregnant female. 3. patients with severe infection or with other immune system diseases.
association of type of anesthetic and outcomes in transfemoral aortic valve replacement

Conditions: Aortic Stenosis

Summary: this study proposes to perform a descriptive analysis and pilot observational study looking at the types and quantity of anesthetic agents used and their associations with outcomes among patients scheduled to receive transfemoral aortic valve replacements (tavr) at yale new haven hospital (ynhh).

this study proposes to perform a descriptive analysis and pilot observational study looking at the types and quantity of anesthetic agents used and their associations with outcomes among patients scheduled to receive tavr at ynhh. hypothesis 1: tavr surgery done under monitored anesthesia care are performed using some combination of the following anesthetics: dexmedetomidine, propofol, fentanyl, and midazolam. hypothesis 2: age-adjusted dosing of these agents will be insufficient to account for extreme age after controlling for preoperative comorbid status. hypothesis 3: the rate of conversion to general anesthesia will be unrelated to the type of conscious sedation used. hypothesis 4: icu length of stay, delirium, hospital length of stay, and length of hospital stay will be shorter for patients who were sedated using dexmedetomidine vs those without. research plan: the research will be done via chart review and analysis of data already contained in the multicenter perioperative outcomes group databases at yale. the possible risks are primarily the risk to privacy that is inherent in any retrospective chart review. the benefit may be to suggest areas of future study to improve sedation practices for tavr at yale and elsewhere. information recorded will include demographic and preoperative medical assessment from prior to the tavr, the anesthetic record, and the post-operative course of recovery for patients undergoing tavr. these data will include age, gender, comorbidities, laboratory values, vital signs, and the results of imaging studies as well as other records potentially related to the above hospitalization.

Eligibility criteria:
inclusion criteria: * patients who underwent tavr at ynhh under planned conscious sedation with monitored anesthetic care exclusion criteria: * patients who received monitored anesthesia care without the receipt of any study intervention drug (propofol, fentanyl, midazolam, or dexmedetomidine).

Keywords: transcatheter aortic valve replacement anesthesia conscious sedation managed anesthesia care
physio-anatomy clinical data collection study

Conditions: Coronary Stenosis

Summary: this is an on-label clinical study design intended for the collection of three different types of interventional procedural data using fda-cleared cardiac catheterization technologies and drugs, each used according to its product labeling and standard practice of medicine.

these devices and drugs are commonly used for patient evaluation during pci procedures performed by interventional cardiologists. the three device technologies used in a single catheterization laboratory visit for assessment of the coronary arteries include: * a coronary angiography imaging system to x-ray the coronary arteries for the evaluation of vessel narrowing or blocking. * pressure guidewire from one or more manufacturers for the measurement of coronary physiology parameters. * gentuity® hf-oct imaging system with vis-rx® micro-imaging catheter for imaging and sizing of the stenosed coronary arteries.

Eligibility criteria:
inclusion criteria: * patients \>18 years of age. * patients provide written informed consent. * clinical presentation consistent with suspected coronary disease. * patients who are candidates for pci and scheduled for coronary diagnostics in the cardiac catheter lab with the intent to perform a physiological assessment for de novo lesions with stenosis, if clinically indicated. exclusion criteria: * presence of acute st elevation myocardial infarction (stemi) at the time of the cath lab procedure. * contraindication for ffr examination or administration of vasodilators. * bacteremia or sepsis. * major coagulation system abnormalities. * severe hemodynamic instability or shock. * heart failure nyha class iv. * severe valvular heart disease. * prior heart transplant. * acute renal failure based on diagnostic practice of the treating physician at time of screening. * patient is pregnant. * patient is currently enrolled in another clinical study that may impact the results of this study. * patient has other co-morbid condition(s) that, in the opinion of the investigator, could limit their
a randomized control trial comparing analgesic benefits of ultrasound-guided single vs continuous quadratus lumborum blocks (qlb)vs intrathecal morphine(itm) for post cesarean section pain

Conditions: Pain, Postoperative

Summary: the purpose of this study is to compare opioid consumption in morphine equivalents between the groups that received postoperative analgesia with intrathecal morphine versus us guided ql blocks versus us guided ql catheters


Eligibility criteria:
inclusion criteria: * elective c section via pfannenstiel incision * living singleton pregnancy * gestation week at least 37 weeks * american society of anesthesiologists (asa) status 1, 2 and 3 * primary and secondary c sections exclusion criteria: * chronic pain * opioid tolerant patients * allergy to drugs used in the study. * cognitive dysfunction * bmi \> 40 * coagulation disorder * local infection * inability to tolerate oral medication * previous intra-abdominal surgery * patients who will receive a combined spinal epidural for their c section * local anesthetics injected at any other fascial plane except the qlb plane (for e.g.- local wound infiltration by surgeon) * patients who received sedation or general anesthesia during their c section (midazolam, ketamine, fentanyl, propofol, hydromorphone)

Keywords: post c section pain pain control after baby nerve block for post delivery pain
nocturnal oxygen therapy

Conditions: Lung Diseases; Lung Diseases, Obstructive; Chronic Obstructive Pulmonary Disease

Summary: to compare the efficacy of long-term use of nocturnal oxygen therapy (12 hours) with that of continuous, low-flow oxygen therapy (24 hours) in patients with chronic hypoxic lung disease.

background: chronic obstructive pulmonary disease is a major health problem in the united states. in 1975, it was the sixth leading cause of death. the economic impact of the disease in 1972 amounted to $803 million in the direct costs of disability treatment, $3.05 billion in disability costs, and $645 million in lost earnings due to premature death. motivated in part by the significant toll of this disease, a conference on the scientific basis of respiratory therapy, co-sponsored by the american thoracic society and the division of lung diseases, examined the current status of the use of oxygen therapy in chronic lung disease. the proceedings of the conference, published in the american review of respiratory disease (vol. 110, no. 6, december 1974), included a recommendation for clinical studies that would provide a critical assessment of the role of nocturnal oxygen therapy in the treatment of patients with chronic obstructive pulmonary disease. low-flow oxygen, administered continuously, was known to benefit some patients with chronic hypoxic lung disease. however, low-flow oxygen administration for long periods of time is cumbersome, confining, and expensive. if nocturnal oxygen administration could be unequivocally demonstrated to be efficacious, then the advantages of convenience and cost would have a favorable impact on treatment of patients, and a rationale could be developed for testing this therapy in a larger group of patients. the planning phase of the trial was initiated in september 1976. patient recruitment began in may 1977. the recruitment phase lasted 24 months. the 203 patients in the trial were assigned randomly to nocturnal oxygen therapy (home) or continuous low-flow oxygen therapy. design narrative: randomized, fixed sample. two hundred and three patients were randomly assigned to at-home treatments of continuous oxygen therapy or nocturnal oxygen therapy. endpoints related to quality of life, neuropsychological function, and respiratory function and capacity. intervention lasted for 6 months to 3 years, with an average intervention of 19.3 months.

Eligibility criteria:
men and women, ages 35 to 70, who had severe chronic obstructive lung disease requiring supplemental oxygen therapy.
real-world effectiveness of osimertinib for patients with non-small cell lung cancer

Conditions: Locally Advanced or Metastatic Non-Small Cell Lung Cancer; EGFR Exon20 Insertion Mutations

Summary: this study is a retrospective real-world study to evaluate the efficacy of osimertinib for patients with advanced or metastatic egfr 20exon insertion mutation (20ins) non-small cell lung cancer.

this is a multicenter, retrospective observational real-world study, which evaluates the efficacy of osimertinib, between 2017 and 2022, in patients with advanced or metastatic egfr 20exon insertion mutation (20ins) non-small cell lung cancer. this study serves as the external control for a single arm phase ii trial on jmt101 combined with osimertinib in patients with non-small cell lung cancer. the primary outcome measure is objective response rate (orr).

Eligibility criteria:
inclusion criteria: 1. locally advanced or metastatic (stage шb-ⅳ, 8th ajcc) nsclc confirmed by histology or cytology; 2. the result of egfr 20ins is positive detected by tissue, blood, pleural fluid or cerebrospinal fluid; 3. have received osimertinib treatment after detection of egfr 20ins; 4. age of 18 years or above; 5. information about tumor outcome evaluation is required at least once after osimertinib treatment (such as tumor imaging data, description of efficacy evaluation in medical records, etc.). exclusion criteria: 1. previously treated with jmt101 (patients will be included if osimertinib treatment is before jmt101 treatment); 2. patients harboring egfr exon20 insertion mutation and also have other egfr tki-sensitizing egfr mutations, such as g719x mutation in exon 18, exon 19 deletion mutation (19 del), exon 20 t790m or s768i mutation, exon 21 l858r mutation, or l861q mutation.
cerebral metabolic changes associated with thalamic stimulation

Conditions: Epilepsy

Summary: the purpose of this research study is to evaluate the brain circuits function and circuits involved in the mechanism of thalamic dbs in patients with medically refractory epilepsy.

deep brain stimulation (dbs) of the anterior nucleus of the thalamus in patients with medically refractory epilepsy has been shown to be efficacious. studies have estimated a 46-76% reduction in seizures relative to the baseline. however, the exact anatomic circuitry involved in the mechanism of dbs in epilepsy remains unknown. positron emission tomography (pet) studies can provide clues to the metabolic activity associated with dbs activation. in our study, patients will be scanned with their dbs electrodes turned "on" and "off". pet data captured during these two distinct states may show characteristic differences in cerebral glucose metabolism and modulatory effects of surrounding cerebral structures, thus providing clues to how dbs works to prevent seizures.

Eligibility criteria:
inclusion criteria: * 18-85 years old * currently have dbs implanted for medically refractory epilepsy * women of childbearing age will be required to use established contraceptive methods while enrolled in the study. exclusion criteria: patients who: * are \ 85 years of age * are medically unstable * are women who are potentially pregnant, pregnant or nursing * have had pet imaging within 1 year.

Keywords: pediatrics epilepsy deep brain stimulation positron emission tomography
phase ii study to assess rg2417 in the treatment of bipolar i depression

Conditions: Bipolar Depression

Summary: the primary purpose of this study is to determine the safety and efficacy of oral rg2417 (uridine) when administered to patients with bipolar i depression twice daily for six weeks.


Eligibility criteria:
inclusion criteria: 1. dsm-iv-tr diagnosis of bipolar i depression 2. 18 to 65 years of age, inclusive 3. depressive phase, as measured by madrs greater than or equal to 20 at screening and day1 4. duration of current depressive episode of at least four weeks by day 1 5. competent to give informed consent exclusion criteria: 1. manic/hypomanic/mixed episode as determined by the mini at screening and/or a young mania rating scale (ymrs) score of \> 12 at screening and/or day 1 2. dementia or any current axis i diagnosis (excluding bipolar i) requiring pharmacological treatments 3. a history of alcohol or substance dependence within six months of day 1, or a history of alcohol or substance abuse within three months of day 1 4. urine drug screen positive for amphetamines, cocaine metabolites, opiates and/or phencyclindine (pcp) 5. an axis ii diagnosis that is likely to interfere with protocol compliance 6. initiation of or increase in psychotherapy within 4 weeks of screening 7. psychotropic medication (excluding fluoxetine) within 24 hours of initiation of study drug on day 1; fluoxetine within 2 weeks of initiation of study drug on day 1 8. serious suicidal or homicidal risk as determined by the investigator and/or a score of \> 5 on the suicide item #10 of the madrs at screening and/or day 1 9. history of sensitivity to any of the ingredients in the study drug 10. clinically significant abnormality in any screening laboratory results 11. clinically significant organic disease, including cardiovascular, endocrine, hepatic, pulmonary, neurologic, or renal disease, or any other medical condition, serious intercurrent illness, or extenuating circumstances that, in the opinion of the investigator, would interfere with the performance or interpretability of, or put the patient at risk from, the study procedures 12. women who are pregnant, breastfeeding, or refuse to use adequate birth control 13. current seizure disorder 14. participation in an investigational drug study within twenty-eight days of day 1 15. current psychotic episode 16. clozaril use and/or electroconvulsive therapy within six months of day 1 17. failure of three or more adequate trials of standard therapies for depression during the current episode 18. current episode of depression is longer than one year

Keywords: manic depression bipolar disorder depression uridine rg2417
18f-naf-pet/mr vs 99mtc-mdp-spect/ct to detect bone metastases in prostate cancer patients.

Conditions: Bone Metastases; Prostate Cancer

Summary: the number of metastases in a patient with primary or recurrent prostate cancer has major prognostic implication. the purpose is to compare, in a pilot study, the diagnostic performance of 18f-naf-pet/mr with respect to the results of the scintigraphy 99mtc-mdp-spect/ct (routine exam) for determining the presence or absence of bone lesions in prostate cancer patient, with up to five metastases (oligo-bone metastatic) based on scintigraphy 99mtc-mdp-spect/ct. the gold standard will be a combination of clinical follow-up, additional imaging and biopsy, as indicated by the multidisciplinary discussion at the tumor board. the findings from whole-body 99mtc-mdp-spect/ct, 18f-naf-pet/mr, and the combination of the 2 modalities will be categorized by 2 teams of 2 readers as benign or probably benign, equivocal, or malignant or probably malignant and compared with the results of follow-up for jafroc and roc analysis.


Eligibility criteria:
inclusion criteria: * oligo- metastatic patient with prostate cancer and bone lesions (up to five metastases) based on scintigraphy and whole-body spect/ct (staging or recurrence). * patient must be able to provide informed consent. * patient is ≥ 18 years old exclusion criteria: * patient with another active malignancy. * patient is \< 18 years old * patients with contraindications of mri procedure (metal implants, cardiac pacemakers, old type of prosthesis) * patients with severe renal impairment (mdrd \< 30)

Keywords: prostate cancer bone metastases pet/mri
bowen therapy and foam rolling in patients with text neck syndrome

Conditions: Neck Pain

Summary: this study aims to compare the effects of both the therapies on postural changes, pain, decreased rom, and functional disability among students suffering from text neck syndrome.


Eligibility criteria:
inclusion criteria: * neck-head trauma * history of surgical intervention in the neck area * neurological deficit * severe neck pain which required medical treatment * cervical disc disease with radiculopathy * inflammatory or malignant type of pain * systematic disease * scoliosis * kyphosis. exclusion criteria: * neck-head trauma * history of surgical intervention in the neck area * neurological deficit * severe neck pain which required medical treatment * cervical disc disease with radiculopathy * inflammatory or malignant type of pain * systematic disease * scoliosis * kyphosis.

Keywords: text neck syndrome neck pain bowen therapy foam rolling
physical activity in insurance medicine: effects on patients with psychiatric disorders

Conditions: Depressive Disorder; Somatoform Disorder; Anxiety Disorder; Personality Disorder

Summary: we will conduct a randomized control trial to investigate whether and to what extent regular and guided group physical activity over 12 weeks (2 sessions à 1 hour/week) improves physical fitness and (physio-)psychological functions (like subjective sleep, mental toughness, perceived stress, self-efficacy, etc.), as well as participation skills and the ability to work, in claimants for a disability pension due to psychiatric disorders, whose ability to work had recently been assessed by means of a psychiatric expert opinion. the control group is designed very similar and implies predominantly sedentary leisure time group activities (e.g. playing board games, doing handicrafts). measures will be performed at baseline, post-test, and at follow ups three and twelve months after post-test, some variables will additionally be assessed 4-weekly during the intervention. we expect that intervention group participants will report and show, respectively, more improved physical fitness, (physio-)psychological functioning and participations skills, as well as increased ability to work, compared to the control group.


Eligibility criteria:
inclusion criteria: * claimants for a disability pension due to a mental disorder, whose ability to work has been recently assessed by means of a psychiatric expert opinion * both genders * 18-55 years old * clinical diagnosis of depressive disorder, somatoform disorder, anxiety disorder, personality disorder * sufficient competence in understanding, speaking and reading german * sufficient cognitive, emotional and social level of functioning to be able to participate in a group * physical activity readiness questionnaire without evidence for reduction * or: physical activity readiness certificated by the general practitioner * informed consent exclusion criteria: * comorbidity with a somatic disorder that limits the ability for physical exercises * pregnancy * ongoing disturbance of the study

Keywords: mental disorders physical activity disability pension disability pension due to mental illness ability to work mental toughness